NP / PA
Bethany Medical Center
Bethany Medical Center was paid $5.17M by Medicaid between Dec 2018 and Dec 2024, across 74 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 26% of everything it billed.
33Billing provider infoBETHANY MEDICAL CENTER
NORTH WILKESBORO, NC 28659
NORTH WILKESBORO, NC 28659
33aNPI1508341736assigned 10/03/2018
33bProvider typeFamily Nurse Practitioner
28Total paid$5.17M
24GClaims185,319
24DCodes billed74
24AFirst – last monthDec 2018 – Dec 2024
Compared with peers
Next to other Family Nurse Practitioner providers in North Carolina
Rank by total paid#2 of 147
Median peer was paid$12K
This provider vs. median448×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 451 | $26K | |
| 2019 | 9,071 | $556K | |
| 2020 | 14,455 | $745K | |
| 2021 | 23,551 | $987K | |
| 2022 | 37,548 | $1.00M | |
| 2023 | 52,738 | $1.13M | |
| 2024incomplete | 47,505 | $724K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 26% | 20,415 | 16,168 | $1.36M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 25% | 25,562 | 19,700 | $1.32M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 20% | 9,915 | 7,840 | $1.03M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 8.1% | 12,477 | 9,521 | $420K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 4.6% | 3,572 | 2,960 | $238K |
| 99199 | Unlisted special service, procedure or report | 3.0% | 23,428 | 13,038 | $158K |
| 99406 | 2.4% | 17,781 | 13,467 | $125K | |
| 83970 | 1.7% | 2,026 | 1,703 | $89K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.3% | 2,112 | 1,774 | $67K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 557 | 427 | $47K |
| 81025 | <1% | 6,733 | 5,394 | $41K | |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | <1% | 483 | 441 | $40K |
62 more codes
| 80053 | Comprehensive metabolic panel | <1% | 2,684 | $25K |
| 86769 | <1% | 656 | $24K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 2,664 | $22K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,281 | $21K |
| 94375 | <1% | 1,042 | $17K | |
| 80061 | Lipid panel | <1% | 1,200 | $16K |
| 83735 | <1% | 1,946 | $14K | |
| 80074 | <1% | 226 | $13K | |
| 84480 | <1% | 822 | $12K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,042 | $9K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 799 | $8K |
| 84439 | <1% | 810 | $8K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 440 | $8K |
| 82607 | <1% | 325 | $5K | |
| 72100 | <1% | 269 | $4K | |
| 93000 | <1% | 327 | $4K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 60 | $3K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 93 | $3K |
| 99443 | <1% | 55 | $3K | |
| 90756 | <1% | 193 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 42 | $2K |
| 99442 | <1% | 66 | $2K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 60 | $2K |
| 99205 | Prolong outpt/office vis | <1% | 14 | $2K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 225 | $1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 60 | $1K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 41 | $1K |
| 86703 | <1% | 68 | $871.37 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 253 | $807.10 |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 25 | $446.26 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 632 | $417.70 |
| 71046 | Radiologic examination, chest; 2 views | <1% | 21 | $277.12 |
| 84550 | <1% | 44 | $236.77 | |
| 86431 | <1% | 33 | $227.85 | |
| 81002 | <1% | 308 | $183.97 | |
| 90688 | <1% | 15 | $163.97 | |
| 82962 | <1% | 84 | $163.89 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 413 | $137.42 |
| 80050 | General health panel | <1% | 14 | $125.18 |
| 99497 | <1% | 114 | $95.27 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 15 | $59.19 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 19 | $53.32 |
| 1159F | <1% | 228 | $6.47 | |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 678 | $2.24 |
| 1125F | <1% | 424 | $0.01 | |
| 3078F | 0% | 5,634 | $0.00 | |
| 4004F | 0% | 823 | $0.00 | |
| 3077F | 0% | 1,113 | $0.00 | |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | 0% | 130 | $0.00 |
| G0444 | Annual depression screening, 5 to 15 minutes | 0% | 127 | $0.00 |
| 3074F | 0% | 6,128 | $0.00 | |
| 3044F | 0% | 94 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 61 | $0.00 |
| 3080F | 0% | 215 | $0.00 | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 0% | 272 | $0.00 |
| 3008F | 0% | 14,815 | $0.00 | |
| 3079F | 0% | 2,875 | $0.00 | |
| 3075F | 0% | 1,031 | $0.00 | |
| 3048F | 0% | 30 | $0.00 | |
| 4010F | 0% | 14 | $0.00 | |
| 1170F | 0% | 52 | $0.00 | |
| G8839 | Sleep apnea symptoms assessed, including presence or absence of snoring and daytime sleepiness | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPETERS, ELISE (PRESIDENT)